Seminars in Cancer Biology

Article	Citations
Editorial Board	436
Editorial Board	407
Deregulated transcription factors in the emerging cancer hallmarks	312
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	238
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	234
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	214
Critical DNA damaging pathways in tumorigenesis	212
Multifaceted role of chemokines in solid tumors: From biology to therapy	207
Advances in biology and novel treatments of SCLC	204
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	202
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	187
Small secretory proteins of immune cells can modulate gynecological cancers	185
Emerging applications of bacteria as antitumor agents	183
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	181
Editorial Board	178
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	174
Editorial Board	172
Gut microbes in gastrointestinal cancers	171
PIWI-interacting RNAs in human cancer	169
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	159
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	159
Innovative trial design in precision oncology	156
Immune cellular components and signaling pathways in the tumor microenvironment	150
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	142
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	138

Anticancer properties of chimeric HDAC and kinase inhibitors	136
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	136
Origins and molecular effects of hypoxia in cancer	135
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	132
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	130
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	128
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	127
Genome chaos: Creating new genomic information essential for cancer macroevolution	123
The IL-1 family in tumorigenesis and antitumor immunity	120
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	118
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	118
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	116
Reprogramming of glycolysis by chemical carcinogens during tumor development	115
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	109
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	109
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	108
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	107
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	106
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	106
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	106
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	105
The intricacies of NRF2 regulation in cancer	105
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	104
Editorial Board	102
Atrial fibrillation in cancer patients: Epidemiology, identification and management	102
Anticancer natural products targeting immune checkpoint protein network	102
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	102
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	101
The role of deiodinases on metabolic alteration in cancer	101
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	101
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	99
How far have we explored fungi to fight cancer?	97
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	97
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	97
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	93
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	92
Editorial Board	91
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	91
Editorial Board	91
The role of RNA processing and regulation in metastatic dormancy	91
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	90
The foundational framework of tumors: Gametogenesis, p53, and cancer	89
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	89
Metabolic reprogramming of tumor microenviroment by engineered bacteria	87
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	86
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	85
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	84
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	83
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	81
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	80

Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	79
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	79
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	78
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	78
Advancements in small cell lung cancer	78
Clinical utility of whole-genome sequencing in precision oncology	77
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	76
The role of tumor microenvironment and exosomes in dormancy and relapse	75
Microbiota and lung cancer	74
Analytical demands to use whole-genome sequencing in precision oncology	73
MITOCHONDRIAL CHOLESTEROL AND CANCER	72
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	72
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	72
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	71
Anticancer activity of lactic acid bacteria	71
Holistic immunomodulation for small cell lung cancer	71
Targeting p53 for the treatment of cancer	70
CRISPR/Cas mediated epigenome editing for cancer therapy	70
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	69
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	68
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	68
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	67
Paradoxes of cancer: Survival at the brink	67
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	67
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	66
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	66
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	66
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	66
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	65
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	65
Excess body weight: Novel insights into its roles in obesity comorbidities	64
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	64
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	64
Editorial Board	64
Thematic issue ‘tumor glycolysis’	64
Editorial Board	63
Editorial Board	63
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	62
SR-BI as a target of natural products and its significance in cancer	61
The central role of mitochondria in the relationship between dietary lipids and cancer progression	61
Human cell polyploidization: The good and the evil	60
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	60
Deregulated transcription factors and poor clinical outcomes in cancer patients	60
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	60
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	59
Transfer RNA-derived small RNA: A rising star in oncology	59
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	59
TGF-β, EMT, and resistance to anti-cancer treatment	58
The impact of VEGF on cancer metastasis and systemic disease	58
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	57
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	57
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	57
Possible connection between diet and microRNA in cancer scenario	56
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	56
Role of endolysosome function in iron metabolism and brain carcinogenesis	56
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	56
Editorial Board	56
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	56
Precision diagnostics in lymphomas – Recent developments and future directions	56
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	55
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	55
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	55
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	55
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	55
The intricate nature of senescence in development and cell plasticity	55
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	54
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	54
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	54
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	54
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	54
Alternative splicing in EMT and TGF-β signaling during cancer progression	54
Transcriptional factors targeting in cancer stem cells for tumor modulation	53
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	53
Gut microbiota and immunosenescence in cancer	52
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	52
Editorial Board	52
cGAS/STING signalling pathway in senescence and oncogenesis	52
Artificial intelligence aids in development of nanomedicines for cancer management	52
Editorial Board	52
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	52

Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	51
Editorial Board	51
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	51
Vitamin D: What role in obesity-related cancer?	51
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	51
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	50
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	50
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	49
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	49
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	49
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	49
The altered lipidome of hepatocellular carcinoma	48
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	48
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	48
Precision medicine in pediatric solid cancers	47
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	47
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	47
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	46
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	46
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	46
Small cell lung cancer: Novel treatments beyond immunotherapy	46
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	46
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	46
Hedgehog signaling mechanism and role in cancer	45
Nanoparticles: Attractive tools to treat colorectal cancer	45
Predictive biomarkers for response to immune checkpoint inhibition	45
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	45
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease	44
Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity	44
Understanding RNA-binding proteins	44
Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities	44
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers	43
The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions	43
Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics	43
Ethical challenges of precision cancer medicine	43
Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer	43
Nutrient sensing of mTORC1 signaling in cancer and aging	43
Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells	43
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies	43
Sphingolipids in embryonic development, cell cycle regulation, and stemness – Implications for polyploidy in tumors	42
Inflammasomes in cancer: Effect of epigenetic and autophagic modulations	42
The two sides of Hippo pathway in cancer	42
Preface for “Extracellular vesicles in cancer, from signalling mechanisms to therapeutic potential”	42
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	42
Vaginal microbiome and cervical cancer	41
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis	41
Editorial Board	41
Targeting stemness of cancer stem cells to fight colorectal cancers	41
New approaches for targeting platinum-resistant ovarian cancer	41
RB functions as a key regulator of senescence and tumor suppression	41
Epigenetic Regulation of Cancer Immune Cells	41
Harnessing computational spatial omics to explore the spatial biology intricacies	41
Targeting cancer stem cells by nutraceuticals for cancer therapy	41
Obesity and renal cell carcinoma: Biological mechanisms and perspectives	41
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy	40
Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer	40
Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence	40
A systems and computational biology perspective on advancing CAR therapy	40
An update on vitamin D signaling and cancer	40
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin	39
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs	39
Immunosenescence in skeletal muscle: The role-play in cancer cachexia chessboard	39
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	39
Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse	39
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells	39
Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?	39
Special issue on “Excess body weight and cancer: Novel biologic insights and challenges”	39
The cell cycle revisited: DNA replication past S phase preserves genome integrity	39
MicroRNA and ER stress in cancer	39
Status quo of Extracellular Vesicle isolation and detection methods for clinical utility	38
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments	38
Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]	38
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	38
New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies	38
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems	38
Extracellular vesicles for precision medicine in prostate cancer – Is it ready for clinical translation?	38
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	38
Extracellular Vesicle (EV) biohybrid systems for cancer therapy: Recent advances and future perspectives	38
Editorial: Regulating cell cycle-related activities: The right target for cancer therapy	38
Editorial Board	37
Special issue: Diet, lipids, and cancer: From Pathogenic mechanisms to potential therapeutic strategies	37
Editorial Board	37
Editorial Board	37
Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression	36
Polyploidy in development and tumor models in Drosophila	36
Special issue: Modulation of immune checkpoint proteins and their networks in cancer progression	36
Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany	36
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1	36
Cancer cell populations	36
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells	36
High-Throughput immunogenetics for precision medicine in cancer	35
Multiple endocrine neoplasia type 2: A review	35
The potential of liquid biopsy in the management of cancer patients	35
The relationship of the microbiome, associated metabolites and the gut barrier with pancreatic cancer	35
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies	35